-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Outperform on Arcus Biosciences, Raises Price Target to $41

Benzinga·04/02/2026 13:00:47
Listen to the news
Wedbush analyst Robert Driscoll maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $37 to $41.